Amgen spotlights preclinical 'multi-specifics' as analyst predicts late-stage M&A
If David Reese gets his way, Lumakras will be the first of many Amgen drugs that shatter the fences currently cordoning off vast swaths of protein targets as “undruggable.”
Lumakras, the groundbreaking KRAS G12C inhibitor 40 years in the making, did not disappoint during its first months as a commercial drug — spurring sales of $36 million in a US launch that analysts said were “off to a strong start.” As Amgen attempts to construct a whole pipeline around and readies a slate of next-gen KRAS candidates, though, SVB Leerink analyst Geoffrey Porges warns it doesn’t have much time before revenue erosion sits in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.